On Tuesday, Citi analyst Patrick Donnelly reaffirmed a Sell rating on Charles River Laboratories International Inc. (NYSE:CRL) with a steady price target of $175.00. The stock, currently trading at $177.82, is near its 52-week low of $176.48, significantly below its peak of $275.00. According to InvestingPro data, analyst targets for the stock range from $164.00 to $260.12.
The reaffirmation follows the company's preliminary financial guidance for fiscal year 2025, which anticipates a decline in organic revenues similar to that of fiscal year 2024, estimated at a 3-4% decrease. This projection falls notably below the consensus expectation of approximately flat organic growth for 2025.
According to Donnelly, Charles River Labs (NYSE:CRL)' Discovery (NASDAQ:WBD) and Safety Assessment (DSA) client demand is expected to mirror the second half of 2024, with biopharmaceutical companies continuing to face challenges due to restructuring and pipeline re-prioritization.
Despite these challenges, InvestingPro analysis shows the company maintains a GOOD overall financial health score, with particularly strong profitability metrics and an Altman Z-Score of 3.73, indicating solid financial stability.
While demand from biotech is projected to see a slight improvement, pricing is still anticipated to be a significant obstacle. Additional factors contributing to revenue declines include an estimated 1% drag from lower commercial Contract Development and Manufacturing Organization (CDMO) revenue, and a 0.5% impact from site consolidations.
The company's operating profit margins (OPMs) for fiscal year 2025 are also expected to modestly decline compared to the previous year, primarily due to the lower revenue forecasts and ongoing pricing pressures. The guidance provided by Charles River Labs paints a picture of financial performance that is below market expectations.
Donnelly's analysis suggests that the financial outlook for Charles River Labs is weaker than anticipated, leading to the reaffirmation of the Sell rating. The $175.00 price target set by Citi reflects the firm's assessment of the company's value in light of the challenges outlined in the guidance.
However, InvestingPro's Fair Value analysis suggests the stock may be undervalued at current levels. Subscribers can access the comprehensive Pro Research Report, which includes detailed financial analysis, valuation metrics, and additional ProTips for smarter investment decisions.
In other recent news, Charles River Laboratories has been the subject of various analyst notes following its preliminary guidance for the year 2025. JPMorgan maintained its Neutral position on the company with a steady price target of $215.00, while TD Cowen reaffirmed a Hold rating on the company's shares with a price target of $227. BofA Securities also maintained a Neutral rating on Charles River Labs with a price target of $210, and Baird maintained a Neutral rating but reduced its price target to $197 from $211.
The company anticipates that its 2025 revenues will organically decline in a range similar to that estimated for 2024, suggesting a decrease of 4% to 3%. This is primarily due to limited demand from large pharmaceutical companies and stable to slightly improving demand from biotech companies. Additionally, a decrease in commercial Contract Development and Manufacturing Organization (CDMO) revenue is projected to lower overall revenue growth by about 1% in 2025.
Charles River Labs expects Discovery Services and Alliances (DSA) trends to continue as they did in the second half of 2024, with DSA pricing anticipated to negatively impact revenue in 2025. Site consolidation efforts are also expected to create a revenue headwind of approximately 0.5% for the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.